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Ischemic retinopathies, including retinopathy of pre-
maturity and diabetic retinopathy, are major causes
of blindness. Both have two phases, vessel loss and
consequent hypoxia-driven pathologic retinal neo-
vascularization, yet relatively little is known about the
transcription factors regulating these processes. Myo-
cyte enhancer factor 2 (MEF2) C, a member of the
MEF2 family of transcription factors that plays an
important role in multiple developmental programs,
including the cardiovascular system, seems to have a
significant functional role in the vasculature. We,
therefore, generated endothelial cell (EC)–specific
MEF2C-deficient mice and explored the role of MEF2C
in retinal vascularization during normal development
and in a mouse model of oxygen-induced retinopa-
thy. Ablation of MEF2C did not cause appreciable de-
fects in normal retinal vascular development. How-
ever, MEF2C ablation in ECs suppressed vessel loss in
oxygen-induced retinopathy and strongly promoted
vascular regrowth, consequently reducing retinal avas-
cularity. This finding was associated with suppression
of pathologic retinal angiogenesis and blood-retinal
barrier dysfunction. MEF2C knockdown in cultured ret-
inal ECs using small-interfering RNAs rescued ECs from
death and stimulated tube formation under stress con-
ditions, confirming the endothelial-autonomous and
antiangiogenic roles of MEF2C. HO-1 was induced by
MEF2C knockdown in vitro and may play a role in the
proangiogenic effect of MEF2C knockdown on retinal
EC tube formation. Thus, MEF2Cmay play an antiangio-
genic role in retinal ECs under stress conditions, and
modulation of MEF2C may prevent pathologic retinal
2548neovascularization. (Am J Pathol 2012, 180:2548–2560;
http://dx.doi.org/10.1016/j.ajpath.2012.02.021)
Retinal neovascularization (NV) is a major cause of blind-
ness in the working-age and pediatric populations owing
to ischemic retinopathies, including retinopathy of pre-
maturity, diabetic retinopathy, and retinal vein occlu-
sions. In these conditions, blood vessel loss [vaso-oblit-
eration (VO)] results in hypoxic retina, which secretes
growth factors that stimulate pathologic retinal angiogen-
esis. This destructive angiogenesis could be prevented
either by direct inhibition of the pathologic NV or by
reducing retinal vessel loss, thus decreasing the hypoxic
stimulus that drives the NV. Current therapeutic strate-
gies focus largely on the former approach of inhibiting the
late stage of pathologic NV. There is great potential in the
alternative strategy of reducing VO or promoting normal
vascular repair, thereby reducing the hypoxic stimulus
that drives the late stage of NV.1–3 It would, therefore, be
highly beneficial to learn more about the factors govern-
ing the extent of VO and normal vascular regrowth in the
ischemic retinopathies.
Animal models of oxygen-induced retinopathy (OIR)
have been highly useful in providing insights into retinal
vascular pathobiology.4 The mouse model of OIR5 has
been widely used in part because of the potential for
genetic manipulation6 and has enabled the assessment
of various factors on retinal VO, vascular regrowth after
injury, and pathologic angiogenesis.2,5–7 This model has
yielded great insights into paracrine factors in the retinal
milieu that regulate the retinal vasculature.2,6,7 Relatively
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genes dictating VO, vascular regrowth, and pathologic
retinal NV in OIR, including relevant transcription factors.
The transcription factor myocyte enhancer factor 2
(MEF2) C is known to play a critical role in cardiovascular
development.8–10 MEF2C is one of four MEF2 proteins,
which compose a distinct class of MADS (MCM1-aga-
mous-deficiens serum response factor)-box family of
transcription factors.11 MEF2 proteins are central regula-
tors of multiple developmental programs and have been
demonstrated to play a pivotal role in the morphogenesis
and myogenesis of skeletal, cardiac, and smooth muscle
cells.12,13 Global deletion of mef2c leads to early embry-
onic lethality due to cardiac defects.10 Of particular in-
terest to us, MEF2C seems to have a significant functional
role in the vasculature. MEF2C is expressed in endothe-
lial cells (ECs) in vivo9 and in vitro.14,15 Targeted deletion
of mef2c in mice leads to severe vascular defects.8,9 Our
laboratory previously found that MEF2C expression and
MEF2-dependent activity in ECs are activated by vascu-
lar endothelial growth factor (VEGF).15 To address
whether MEF2C has a role in retinal vascular regulation,
we generated EC-specific MEF2C knockout mice and
investigated the function of MEF2C in OIR. We found that
inactivation of MEF2C reduces retinal blood vessel loss
and promotes retinal revascularization in OIR, thereby
suppressing pathologic retinal NV. In addition, knock-
down of MEF2C promotes angiogenesis of cultured reti-
nal ECs. Together, the results of these studies suggest
that MEF2C has an important inhibitory role in regulating
retinal vascularization under stress conditions.
Materials and Methods
Animals
To generate mice that lack mef2c in ECs, Tie2-Cre trans-
genic (Tie2-Cre) mice16 were first crossed with mice that
carry the conventional exon 2–deleted allele of mef2c
(mef2c2)10 to generate Tie2-Cre/mef2c/2 mice.
These genes are on the same chromosome, making the
Tie2-Cre and mef2c deletion linked in subsequent breed-
ing. These mice were then mated with mef2cloxp/loxp
mice17,18 to generate Tie2-Cre/mef2cloxp/2 EC-specific
mef2c-deficient mice (referred to as mef2cEC) and lit-
termate mice mef2c/loxp (referred to as control). The
genotypes of mef2cEC mice and control mice were
identified by PCR analysis of DNA isolated from tail sam-
ples. The PCR primers were as follows: Tie2-Cre forward:
5=-ACCAGCCAGCTATCAACTCG-3=, Tie2-Cre reverse:
5=-TTACATTGGTCCAGCCACC-3=; MEF2C lox forward:
5=-TTCAGGTGACCTCATTTGAACC-3=,MEF2C lox reverse:
5=-GGAGCCATTGCTCATAAGAAAG-3=; and MEF2C neo-
mycin forward: 5=-GGCATGCTGGGGATGCGGTGGGC-
3=,MEF2C neomycin reverse: 5=-GTCACCTTAAGACATA-
AAGCACCCTCC-3=. ROSA 26 reporter (R26R) mice
[B6.129S4-Gt(ROSA)26Sortm1Sor/J; The Jackson Labora-
tory, Bar Harbor, ME]19 were used to cross with Tie2-Cre
transgenic mice or Tie2-Cre/mef2c/2 mice to monitor
the specific expression of Cre recombinase under thecontrol of Tie2 promoter. All the animal procedures were
approved by the Institutional Animal Care and Use Com-
mittee of the Johns Hopkins University School of Medi-
cine and were conducted in accordance with the Asso-
ciation for Research in Vision and Ophthalmology
Statement for the Use of Animals in Ophthalmic and Vi-
sual Research.
Mouse Model of OIR
The OIR mouse model was described previously by
Smith et al.5 Briefly, mef2cEC mice and control litter-
mates at postnatal day (P)7 along with their nursing moth-
ers were put into an oxygen chamber and exposed to
75% oxygen for 5 days. At P12, mice were removed from
the chamber and were maintained in room air for 5 days
until P17. Mice were euthanized at different time points,
and retinas were harvested for whole-mount staining or
were processed for immunohistochemical staining.
Retinal Whole-Mount Preparations and Staining
Retinal whole-mount staining was performed as previ-
ously described.20 Briefly, whole eyes were fixed in 4%
paraformaldehyde for 30 minutes at room temperature.
After the corneas and lenses were removed, the eyecups
were fixed in 4% paraformaldehyde for 10 more minutes,
and the retinas were carefully dissected. After 1 hour of
blocking in 10% normal goat serum in PBST (PBS plus
3% Triton X-100; Roche Diagnostics GmbH, Mannheim,
Germany), the retinas were incubated with Alexa Fluor
594–conjugated isolectin GS-IB4 from Griffonia simplici-
folia (Invitrogen, Carlsbad, CA) or rat anti–platelet endo-
thelial cell adhesion molecule 1 (PECAM-1) antibody (BD
Biosciences, San Jose, CA) at 4°C overnight. For PECAM
immunostaining, retinas were washed in PBST and then
were incubated with anti-rat IgG conjugated with Alexa
Fluor 488 or 594 antibodies (Invitrogen) at 4°C overnight.
Anti-NG2 chondroitin sulfate proteoglycan (Millipore, Bil-
lerica, MA) was used for immunostaining of pericytes.21
After four 1-hour washes in PBST, retinas were flat
mounted on slides in Fluoromount-G (Electron Micros-
copy Sciences, Hatfield, PA). Retina whole-mount im-
ages were taken using a Zeiss AxioVision microscope
(Carl Zeiss Microscopy LLC, Thornwood, NY) at 50
magnification. For LacZ staining, Tie2-Cre/R26R and
R26R mice at P3 and P30 were euthanized, and eyes
were fixed in 0.5% glutaraldehyde for 5 minutes. After
lens removal, eye cups were fixed in 0.5% glutaralde-
hyde for 10 minutes. Retinas were isolated and washed in
PBS three times and then were stained in X-Gal staining
solution (0.1% w/v X-Gal, 5 mmol/L K3Fe(CN)6, 5 mmol/L
K4Fe(CN)6.6H2O, and 2 mmol/L MgCl2) at 37°C overnight.
After staining, retinas were mounted on slides in Aqua-Poly/
Mount solution (Polysciences Inc., Warrington, PA).
Quantitation of Retinal VO and Pathologic NV
Retinal VO and NV were quantitated as previously de-
scribed.20 Briefly, images of each of the four quadrants of
retina were imported into Adobe Photoshop CS2 (Adobe
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merged to produce one image of each entire retina. VO
and pathologic NV areas were quantified by comparing
the number of pixels in the VO or NV area with the total
number of pixels in the retina.
Immunohistochemical and Immunofluorescence
Staining for Retinal Frozen Sections
Mice were sacrificed on P9, and eyes were enucleated
and directly embedded in optimal cutting temperature
medium (Electron Microscopy Sciences) at 80°C. Sec-
tions (10 m) were cut and fixed in cold 4% paraformal-
dehyde. For immunohistochemical staining, sections
were first blocked with 10% normal swine serum in 0.05
mol/L Tris-buffered saline and then were incubated with
biotinylated lectin (1:40; Vector Laboratories, Burlin-
game, CA) for 2 hours. After washes in Tris-buffered
saline, a 1:100 dilution of horseradish peroxidase avidin
D (Vector Laboratories) was added. Diaminobenzidine
substrate solution was applied later to visualize antibody
binding. For immunofluorescence staining, sections were
fixed as described previously herein and were blocked in
5% normal goat serum for 1 hour. After overnight incu-
bation with anti-MEF2C antibody (Cell Signaling Technol-
ogy Inc., Beverly, MA) and anti–PECAM-1 antibody (BD
Biosciences) at 4°C, sections were washed in Tris-buff-
ered saline plus 0.1% Tween 20 and then were stained
with anti-rabbit IgG conjugated with Alexa Fluor 488 (In-
vitrogen) and anti-rat IgG conjugated with Cy3 (Jackson
ImmunoResearch Laboratories Inc., West Grove, PA).
Hoechst 33258 (Invitrogen) was used to stain nuclei.
Photographs were taken using a Zeiss LSM 710 confocal
microscope (Carl Zeiss Microscopy LLC).
Measurement of Apoptosis in Retina Vessels
To detect EC apoptosis in mouse retina under hyperoxic
conditions, pups were exposed to 75% oxygen for 16
hours, and retinal cryosections were prepared as de-
scribed previously herein. Ten-micrometer serial sec-
tions were cut and collected from the iris root to the
optic nerve. The apoptotic cells were labeled using the
ApopTag Plus fluorescein in situ apoptosis detection kit
(Millipore). After washing in PBS for 10 minutes, the
sections were incubated with anti–PECAM-1 antibody to
stain ECs. The retinal sections were also counterstained
with Hoechst 33258 for nuclei staining. For each section,
images were taken using a Zeiss LSM 710 confocal mi-
croscope. To quantify the apoptotic ECs, cells with both
PECAM- and fluorescein-positive staining were counted.
The data are presented as the mean number of apoptotic
ECs per section.
Blood-Retinal Barrier Assay
The blood-retinal barrier assay was performed as previ-
ously described.22,23 Mice at P17 with OIR were given an
i.p. injection of 1 Ci/g body weight of [3H]-mannitol. One
hour after injection, the mice were sedated and retinasrapidly removed and dissected to free the lens, vitreous,
and any retinal pigment epithelium. The retinas were
placed into preweighed scintillation vials. The thoracic
cavity was opened, and the left superior lobe of the lung
was removed, blotted to remove excess blood, and
placed in another preweighed scintillation vial. A left dor-
sal incision was made, and the retroperitoneal space was
entered without entering the peritoneal cavity. The renal
vessels were clamped, and the left kidney was removed,
cleaned of all fat, blotted, and placed into a preweighed
scintillation vial. The remaining droplets on the tissues
were allowed to evaporate for 20 minutes. The vials were
weighed, and the tissue weights were calculated. One
milliliter of NCSII solubilizing solution (Amersham, Chi-
cago, IL) was added to each vial, and the vials were
incubated overnight in a 50°C water bath. Solubilized
tissue was brought to room temperature and decolorized
with 20% benzoyl peroxide in toluene in a 50°C water
bath. After reequilibration to room temperature, 5 mL of
scintillation fluid CytoScint ES (Fisher Scientific, Pitts-
burgh, PA) and 30 L of glacial acetic acid were added.
The vials were stored for several hours in darkness at 4°C
to eliminate chemiluminescence. Radioactivity was
counted using a liquid scintillation counter (LS 6500;
Beckman Coulter Inc., Brea, CA). The counts per minute
per milligram tissue measured for lung, kidney, and retina
from mef2cEC mice and control mice were used to
calculate the retina/lung and retina/kidney ratios.
Cell Culture
Human retinal ECs (HRECs; Cell Systems, Kirkland, WA)
were cultured in EGM-2MV medium (Lonza Inc., Walkers-
ville, MD) in a humidified 5% CO2 incubator at 37°C, and
the medium was changed every 2 to 3 days. HRECs were
grown in fibronectin (Invitrogen)-coated dishes and were
used at passages 6 to 10.
siRNA Transfection
HRECs were transfected with 25 nmol/L negative control
small-interfering RNA (siRNA) (AM4611; Ambion, Austin,
TX) and MEF2C siRNA (#1, 106791; #2, 143535; Ambion)
or heme oxygenase-1 (HO-1) siRNA (s6673; Ambion)
using siPORT amine transfection reagent (Ambion) ac-
cording to the manufacturer’s instructions. Forty-eight
hours after transfection, cells were treated with or without
H2O2 for 15 minutes and then were used for further as-
says. Specific knockdown of MEF2C and HO-1 were con-
firmed by real-time PCR and Western blot analysis.
Western Blot Analysis
After treatment, cells were washed with PBS and lysed in
Laemmli sample buffer (Bio-Rad Laboratories, Hercules,
CA). The protein samples from total cell lysates were
subjected to 10% SDS-PAGE and were transferred to
Hybond ECL nitrocellulose membrane (Amersham Bio-
sciences, Piscataway, NJ). After incubating with appro-
priate primary and secondary antibodies, the blots were
detected using the SuperSignal West Pico or Femto
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Rockford, IL). For reprobing, the blots were washed in
Western blot stripping buffer (Thermo Fisher Scientific
Inc, Rockford, IL) for 10 minutes before proceeding with
new blotting. Rabbit monoclonal MEF2C antibody (1:
1000) was purchased from Cell Signaling Technologies.
Rabbit polyclonal anti–HO-1 antibody (1:1000) was from
Enzo Life Sciences International Inc. (Plymouth Meeting,
PA). Monoclonal glyceraldehyde-3-phosphate dehydro-
genase antibody (1:2000; Abcam Inc., Cambridge, MA)
was used for loading control.
Apoptosis Assay
For the measurement of in vitro apoptosis, siRNA-trans-
fected HRECs were treated with 300 mol/L H2O2 in
endothelial basal medium 2 (EBM2)  2% fetal bovine
serum for 6 hours, and caspase-3/7 activity was mea-
sured using a Caspase-Glo 3/7 assay kit (Promega
Corp., Madison, WI) according to the manufacturer’s in-
structions.
Tube Formation Assay
EC tube formation was evaluated using a two-layer col-
lagen gel mixture assay, as previously described.24–27
Forty-eight hours after siRNA transfection, HRECs were
trypsinized, and 7  104 cells were seeded on top of the
lower collagen gel layer in each well of the 24-well plate.
After overnight culture, cells were then treated with dif-
ferent doses of H2O2 in EBM2  2% fetal bovine serum
for 5 hours. Medium was then removed, and 150 L of
collagen gel mixture was added to each well. After 2
hours of gel polymerization at 37°C, 500 L of medium
containing H2O2 was added to the upper layer of colla-
gen gel. Eighteen hours later, six random fields in each
well were chosen and photographed using an Axiovert
200M microscope (Carl Zeiss Microscopy LLC), and total
tube length in each field was measured using ImageJ
version 1.41o (NIH, Bethesda, MD). Each experimental
condition was assayed in triplicate, and at least three
independent experiments were performed.
Cell Proliferation Assay
EC proliferation activity was measured using the CellTiter
96 AQueous One Solution Cell proliferation assay (Pro-
mega Corp.).28 Twenty-four hours after siRNA transfec-
tion, cells were trypsinized and seeded into each well of
a 96-well plate at a cell density of 2500 cells. The cells
were serum starved in EBM2 supplemented with 2% fetal
bovine serum for 2 to 3 hours, and the medium was
replaced with 100 L of fresh EBM2 with 2% fetal bovine
serum containing 10 ng/mL VEGF. After 72 hours of in-
cubation, 20 L of MTS reagent from the kit was added to
each well and was incubated at 37°C in 5% CO2 for 2
hours. The plates were shaken thoroughly, and absor-
bance was measured using a microplate reader (FLUO-
star OPTIMA; BMG Labtech GmbH, Ortenberg, Ger-
many) at 492 and 620 nm.Cell Migration Assay
Modified Boyden chambers containing polycarbonate
membranes (Transwell, 8-m pore size; Corning Inc.,
Lowell, MA) coated with 10 g/mL collagen were used for
migration assay.28 Forty-eight hours after siRNA transfec-
tion, cells were washed twice with PBS and serum
starved in EBM2  0.1% bovine serum albumin over-
night. The next day, cells were trypsinized and seeded
onto a collagen I–coated Transwell plate at 6  104 per
well, and 10 ng/mL VEGF was added to the lower cham-
ber. After incubation at 37°C for 4 hours, the stationary
cells on the top of the membrane were removed by a
cotton swab, and the migrated cells on the bottom of the
membrane were stained with DAPI. Ten photographs for
each well were randomly taken under a microscope
(Zeiss Axiovert 200) at 20 objective, and cells were
counted using ImageJ.
Recombinant Adenovirus Infection
Adenovirus encoding green fluorescent protein and con-
stitutively active MEF2C were gifts from Dr. Jeffery Molk-
entin (University of Cincinnati, Cincinnati, OH).29 The
cDNA for constitutively active MEF2C encodes amino
acids 1 to 143 of MEF2C fused to the VP16 transcriptional
activation domain. Adenoviruses were used to infect
HRECs at multiplicities of infection of 10 and 25. Forty-
eight hours after infection, cells were washed twice with
PBS, and proteins were extracted using Laemmli buffer.
Microarray Analysis
HRECs were transfected with either control or MEF2C
siRNA for 24 hours. For profiling of mRNA, total RNA was
extracted using the RNeasy mini kit (Qiagen Inc., Valencia,
CA) according to the manufacturer’s instructions. RNA am-
plification and labeling procedures were performed by us-
ing the Low RNA Input Fluorescent Linear Amplification kit
(Agilent Technologies, Palo Alto, CA). RNA spike-in controls
(Agilent Technologies) are added to RNA samples before
amplification and are labeled according to the manufactur-
er’s protocol. Amplified RNA (from control versus MEF2C
siRNA transfection) was labeled with either Cy3 or Cy5, and
the two labeled pools were mixed for microarray analysis.
Whole human genome microarrays (G4112F; Agilent Tech-
nologies) were used that contain 41,000 probes measuring
approximately 21,000 unique transcripts. Microarrays were
scanned using an Agilent G2505B scanner controlled by
Agilent Scan Control software version 7.0 (Agilent Technol-
ogies). Data were extracted using Agilent Feature Extrac-
tion software version 9.1 (Agilent Technologies). Differen-
tially expressed targets were identified by using processed
data and PValueLog ratios generated by software.
Statistical Analysis
Data are presented asmean SD ormean SEM. Student’s
t-test was used to perform statistical analysis. Multiple groups
were compared by using one-way analysis of variance. A
value of P  0.05 was considered statistically significant.
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Expression of MEF2C in Mouse Retina
MEF2C is known to be expressed in ECs systemically.
We investigated the localization of MEF2C in the mouse
retina at P9 and P35. Immunofluorescence staining anal-
ysis demonstrated nuclear localization of MEF2C (Figure 1),
consistent with its role as a transcription factor. Co-im-
munostaining with endothelial marker PECAM-1 revealed
MEF2C expression in ECs from superficial and deep ret-
inal vessels at P9 (Figure 1). At P35, retinal vessels con-
tinued to exhibit MEF2C staining. Aside from retinal ECs,
MEF2C was also strongly expressed in some non-EC
types distributed in the ganglion cell layer and inner
nuclear layer (Figure 1).
EC-Specific Ablation of mef2c
Since knockout of the mef2c gene is embryonic lethal
due to severe cardiac defects, we selectively knocked
out mef2c in vascular ECs using Tie2-driven Cre ex-
pression. A similar approach has previously been used to
study selective mef2c ablation in multiple other cell
types.18,30–33 EC-specific mef2c-deficient mice were
generated by crossing Tie2-Cre/mef2c/2 mice with
mef2cloxp/loxp mice. Heterozygous mef2c/loxp mice were
indistinguishable from wild-type mice and served as lit-
termate controls. Retinal vascular endothelial targeting of
Figure 1. Expression of MEF2C in retinal ECs. Frozen eye sections from P9
mice (top and middle panels) and P35 mice (bottom panel) were labeled
with MEF2C antibody (green), PECAM-1 antibody (red) to visualize vessels,
and Hoechst 33258 (blue) for nuclear staining. MEF2C was expressed in ECs
from superficial and deep vascular layers and was also evident in choroidal
vasculature. Besides ECs, there was prominent staining of MEF2C in non-ECs
in the ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear
layer (ONL). Hoechst counterstaining clearly demonstrated MEF2C localiza-
tion primarily in the cell nucleus. Scale bars: 100 m (top and bottom
panels); 20 m (middle panel).Tie2-Cre was evaluated by crossing Tie2-Cre transgenicmice with R26R mice.34 X-Gal staining of whole-mount
retina from Tie2-Cre/R26R mice revealed Cre recombina-
tion activity exclusively in the retinal vascular network
(see Supplemental Figure S1 at http://ajp.amjpathol.org).
In contrast, no staining was found in Tie2-Cre–negative
R26R retinas.
Normal Retinal Vascular Development in Mice
with EC-Specific Ablation of MEF2C
We first investigated the impact of EC-specific ablation of
mef2c on retinal vascular development in mice. At P5,
there was no significant difference in vascularized area
between mef2cEC and control mice (Figure 2, A–C). At
P17, the ganglion cell layer, inner nuclear layer, and
photoreceptor layers were histologically similar between
mef2cEC and control mice (Figure 2, D and E). Super-
ficial and deep retinal vessels were present and similar in
both groups of mice (Figure 2, D and E). Therefore,
EC-specific ablation of MEF2C did not cause abnormal-
ities in normal retinal vascular development.
Attenuation of Retinal VO and Reduced
EC Apoptosis in Endothelial-Specific
mef2c-Deficient Mice
We then proceeded to investigate the possible role of
MEF2C on retinal vascular health in a pathologic setting
using the OIR model.5,6 In this widely used model for the
study of ischemic retinopathies, including retinopathy of
prematurity, hyperoxic exposure is used to induce retinal
VO in neonatal mice.5,6 Retinal ischemia, in turn, results
in the up-regulation of multiple proangiogenic growth fac-
tors, stimulating pathologic retinal NV. In this model,
physiologic retinal revascularization does occur, albeit at
a relatively slow rate. Therefore, therapeutic strategies
that accelerate retinal revascularization (and thereby re-
duce retinal ischemia) in this model significantly inhibit
pathologic NV.35,36
We studied the expression of MEF2C in the hyperoxic
(P8) and hypoxic (P14) phases of the OIR model. MEF2C
immunostaining was observed in a subset of ECs at P8.
Significantly increased MEF2C expression in ECs was
apparent at P14 (see Supplemental Figure S2 at http://
ajp.amjpathol.org). Hoechst counterstaining clearly dem-
onstrated MEF2C localization primarily in the cell nu-
cleus. We investigated the effect of EC-specific mef2c
ablation on hyperoxia-induced retinal VO. Hyperoxia-in-
duced VO is known to be rapid, reaching a peak level of
VO within 48 hours after the onset of oxygen exposure (ie,
P9).6,37 No differences in the retinal vasculature between
mef2cEC and control mice were noted at P9 in room air
(Figure 3, A and B), consistent with the observations of
normal retinal vascular development at P5 and P17 (Fig-
ure 2). At P9 in OIR, however, there was significantly
reduced retinal VO in mef2cEC mice (Figure 3, C and
D), with approximately 37% less VO in mef2cEC mice
compared with in littermate controls (Figure 3E).
It is known that hyperoxia-induced EC apoptosis con-
tributes to vessel regression.38 We studied EC apoptosis
17. GCL
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hours) since the maximal degree of VO (and retinal avas-
cularity) is known to occur at P9 in OIR.6 There was
significant reduction (approximately 28%) in TUNEL-pos-
itive ECs in mef2cEC mice compared with in control
mice (P  0.007; Figure 3, F–H). We also found prominent
TUNEL-positive cells distributed in the inner nuclear layers
of control mice and mef2cEC mice (Figure 3, F and G).
Figure 2. mef2cEC mice display no significant difference in normal retin
control mice (A) and mef2cEC mice (B) at P5 were stained with anti-PECA
area. No significant difference was observed (n  3 to 7; P  0.59). Da
counterstaining of hematoxylin in control (D) and mef2cEC (E) retinas at P
Scale bars: 500 m (A and B); 50 m (D and E).Marked Improvement in Retinal
Revascularization Associated with Reduced
Pathologic NV in mef2cEC Mice
After the initial phase of retinal VO, induced by the hy-
peroxic stimulus, the retina undergoes a second phase
characterized by a degree of “physiologic” retinal revas-
lar development compared with control mice. Retina whole mounts from
antibody for retinal vasculature. C: Quantification of the retinal vascularized
iven as mean  SD. Histochemical staining of lectin for vasculature and
, ganglion cell layer; INL, inner nuclear layer; and ONL, outer nuclear layer.
Figure 3. Decreased VO and EC apoptosis in
mef2cEC mice during the hyperoxia phase
in the mouse OIR model. There is no vessel loss
in mef2cEC mice or their control littermates at
P9 in room air (RA) (A and B) as demonstrated
by staining vasculature with GS lectin–Alexa
Fluor 549. Retinal VO at P9 (C and D) is shown
by staining vasculature with GS lectin–Alexa
Fluor 549, as described in Materials and Meth-
ods. Avascular areas are highlighted with white
dashed lines. Scale bars: 500 m. E: mef2cEC
mice had significantly less avascular retinal area
than did control mice at P9 (n  5 to 11 per
group). Data are given as mean  SD. ***P 
0.0001. After 16-hour exposure to 75% oxygen,
apoptosis of ECs in control (F) and mef2cEC
(G) retinas was detected using the TUNEL stain-
ing (green) method and co-immunostaining with
anti-PECAM antibody (red). Nuclei are stained
with Hoechst 33258 (blue). Arrows show apop-
totic ECs. Scale bars: 50 m. GCL, ganglion cell
layer; INL, inner nuclear layer; and ONL, outer
nuclear layer. H: The number of retinal ECs un-
dergoing apoptosis is significantly decreased in
mef2cEC mice (n  7, 12.0  1.8) compared
with in their control littermates (n  9, 16.6 
2.3). Data are given as mean  SD. **P  0.001.al vascu
M (red)
ta are g
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inal NV.6 The amount of pathologic preretinal NV is in-
versely related to the degree of vascular recovery since
the latter dictates the extent of retinal hypoxia/ischemia
that drives NV.6 As shown in Figure 4, A and B, there was
a dramatic reduction in avascular retinal area in
mef2cEC mice compared with in littermate controls at
P12 and P17. Specifically, avascular area was signifi-
cantly decreased 50% in endothelial-specific MEF2C
knockout mice compared with in littermate controls at
P12. At P17, littermate control mice exhibited an almost
fourfold increase in avascular retina compared with
mef2cECmice (Figure 4B), indicating a markedly higher
degree of retinal revascularization in mef2cEC mice
compared with in controls. Associated with this reduction
in avascular retina, mef2cEC mice exhibited signifi-
cantly less (2.3-fold decrease) pathologic retinal NV (Fig-
ure 4C). The vessels in the revascularized area in
mef2cEC mice were covered by pericytes, as demon-
strated by the expression of NG2 (Figure 4D).
In addition to the structural end point of revasculariza-
tion, we also looked at the functional end point of isch-emia-induced vascular leakage in OIR. At OIR P17, in-
creased blood-retina barrier breakdown was found in
control mice, an approximately fivefold increase for the
leakage ratio of retina to lung and a sixfold increase for
the leakage ratio of retina to kidney (Figure 5). In contrast,
endothelial-specific MEF2C knockout mice showed a sig-
nificant decrease of the blood-retinal barrier compared
with control mice at P17 in the OIR model.
MEF2C Knockdown Rescues Retinal ECs from
Oxidative Stress–Induced Cell Death
The present results in the mouse model of OIR indicate
that MEF2C plays an antiangiogenic role in ECs in this
setting since ablation of the mef2c gene results in re-
duced VO and EC apoptosis and in a dramatic increase
in revascularization. To gain further insights into MEF2C
function, we investigated the effect of MEF2C knockdown
in cultured HRECs. In particular, we were interested in the
response to oxidative stimuli, as oxidative stress is known
Figure 4. Ablation of MEF2C in ECs stimulates
vascular recovery and inhibits pathologic NV. A:
Retinal VO and NV of mef2cEC mice and con-
trol mice at P12 and P17 are shown by staining
retinal vasculature with GS lectin–Alexa Flour
549. Avascular areas are highlighted with white
dashed lines. Scale bars: 500 m. B: Quantifi-
cation of VO area at P12 and P17. mef2cEC
retinas show significantly enhanced vascular re-
covery compared with control retinas (n  3 to
4 for P12; n  5 to 10 for P17). *P  0.05, ***P 
0.001. C: mef2cEC mice have reduced patho-
logic NV areas at P17 (n  5, 4.4%  1.9%)
compared with littermate control mice (n  10,
10.3%  2.7%). ***P  0.001. D: The staining of
pericytes in mef2cEC and control mice at P17 in
the OIR model. Whole-mount retinas were stained
with NG2 antibody (green) for pericytes and with
PECAM-1 antibody (red) to visualize vessels. Scale
bars: 200 m. Data are given as mean  SD.to be a major regulator of the retinal vascular response in
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duced EC apoptosis (Figure 3H), we first investigated the
effect of MEF2C knockdown on retinal EC survival.
MEF2C protein levels in HRECs were significantly re-
duced by two different MEF2C siRNA species compared
with control siRNA (Figure 6A). Exposure to H2O2 signif-
icantly increased EC apoptosis, as expected (Figure 6B).
However, EC apoptosis was dramatically reduced by
MEF2C knockdown compared with control siRNA (Figure
6B). These data indicate that inhibiting MEF2C expres-
sion might help retinal ECs survive under oxidative stress
conditions.
MEF2C Knockdown in Retinal ECs Stimulates
Tube Formation under Basal Conditions and
Oxidative Stress
In the OIR model, mice with EC-specific ablation dis-
played significantly increased retinal revascularization
(Figure 4B). We investigated the effect of MEF2C knock-
down on in vitro angiogenesis. We used a tube formation
assay that has previously been used for retinal ECs.24–27
Under basal conditions and oxidative stress, knockdown
of MEF2C using two different siRNAs resulted in signifi-
cantly increased retinal EC tube formation compared with
control siRNA (Figure 7 and see Supplemental Figure S3
at http://ajp.amjpathol.org). The degree of stimulation of
Figure 5. EC-specific MEF2C knockout mice displayed decreased retinal
vascular leakage at P17 in the OIR model. A: The leakage ratio of retina to
lung. B: The leakage ratio of retina to kidney. Data are given as mean  SEM
(n  4 to 10). *P  0.01. RA, room air.tube formation by MEF2C knockdown was comparablewith the stimulation of tube formation by VEGF (10 ng/mL)
in control siRNA-transfected HRECs (see Supplemental
Figure S4A at http://ajp.amjpathol.org). Although MEF2C
knockdown resulted in significant stimulation of tube for-
mation, it had no significant effect on VEGF-induced cell
proliferation or migration (see Supplemental Figure S4, B
and C, at http://ajp.amjpathol.org). These data suggest an
inhibitory role of MEF2C in angiogenesis under basal and
stress conditions.
HO-1 Induction Is Involved in the Proangiogenic
Effect of MEF2C Knockdown on EC Tube
Formation
Given the role of MEF2C as a transcription factor, we
looked at possible changes in gene expression resulting
from the inhibition of MEF2C. We found that knockdown
of MEF2C resulted in significant up-regulation of multiple
angiogenesis-related genes through cDNA array analy-
sis, including HO-1, angiopoietin 2, angiopoietin-like 4,
fibroblast growth factor 2, and transforming growth factor
 2 (Table 1). There was no change in VEGF-A expres-
sion in this microarray study (data not shown). Of these
genes, induction of HO-1 was especially significant and
interesting. HO-1 is an essential enzyme in heme catab-
olism and plays a major protective role in cells against
stress condition. We confirmed by Western blot analysis
that MEF2C knockdown resulted in significant up-regula-
Figure 6. MEF2C regulates H2O2-induced apoptosis in HRECs. A: HRECs
were transfected with negative control siRNA (siCTL) or one of two different
MEF2C siRNAs (siMEF2C #1 and #2) for 48 hours, and knocking down of
MEF2C was confirmed by Western blot analysis to detect MEF2C protein
level. B: After siRNA transfection, cells were treated with 300 mol/L H2O2
for 6 hours. Knocking down of MEF2C significantly decreases H2O2-induced
apoptosis in HRECs. Data are from the average values of five independent
experiments. Data are given as mean  SD. *P  0.05, **P  0.01. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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overexpression of constitutively active MEF2C resulted in
significant down-regulation of HO-1 (see Supplemental
Figure S5 at http://ajp.amjpathol.org).
To determine the functional importance of HO-1 in
MEF2C action, we performed experiments with siRNA-
mediated knockdown of HO-1 and MEF2C. HO-1 siRNA
was effective at reducing HO-1 protein expression (Fig-
ure 8B). The beneficial effect of MEF2C knockdown on
HREC tube formation observed in Figure 7 was abro-
Figure 7. MEF2C regulates the tube formation ability of HRECs with or
without H2O2 treatment. A: Representative images of tube formation assay
with HRECs after transfection with control siRNA (siCTL) and MEF2C siRNA
(siMEF2C). Scale bar 100 m. B: After treatment with 300 mol/L H2O2, cells
with decreased MEF2c expression exhibit stronger tube formation ability than do
control cells. Data are from the average values of four independent experiments.
Data are given as mean  SD. *P  0.01 compared with siCTL.
Table 1. Multiple Angiogenesis-Related Genes Up-Regulated in M
Gene symbol
Accession
number
HMOX1 NM_002133 Heme oxygenase (decyc
PLAU NM_002658 Plasminogen activator, u
TGFB2 NM_003238 Transforming growth fac
ANGPTL4 NM_139314 Angiopoietin-like 4
FGF18 NM_003862 Fibroblast growth factor
FGF2 NM_002006 Fibroblast growth factor
ANGPT2 NM_001147 Angiopoietin 2
S100A7 NM_002963 S100 calcium binding pr
HS6ST1 NM_004807 Heparan sulfate 6-O-sulf
JUN NM_002228 Jun oncogene
CEACAM1 NM_001024912 Carcinoembryonic antige
LAMA5 NM_005560 Laminin, alpha 5
ARHGAP22 NM_021226 Rho GTPase activating proteingated when there was concomitant HO-1 knockdown. We
observed this under basal conditions and in the presence
of oxidative stress stimuli (Figure 8, C and D). This finding
indicates that induction of HO-1 plays an important role in
the beneficial effects of MEF2C knockdown on HREC,
although there are likely to be other genes that are also
involved in this beneficial effect.
Discussion
Although current therapies for ischemic retinopathies fo-
cus largely on the late stage of pathologic retinal NV,
there is great rationale for the strategy of reducing the
retinal avascularity that provides the driving force for
retinal NV. Such a strategy could result in reducing VO,
increasing retinal revascularization, or a combination of
the two. It is, therefore, of great benefit to learn more
about the mechanisms that govern these processes. A
great deal of insight has been gained using the OIR
model, especially regarding the paracrine factors in the
retinal milieu that regulate the retinal vasculature in this
model. In contrast, relatively less is known about the EC
intrinsic factors that play a role, including transcription
factors that regulate ECs in OIR.
MEF2C is expressed in ECs,9,14,15 and global deletion
of mef2c leads to severe vascular defects in mice, sug-
gesting an important functional role of MEF2C in ECs.8,9
We were, therefore, interested in the possible role that
MEF2C might play in ECs in the retina in developmental
and pathologic settings. We first confirmed the expres-
sion pattern of MEF2C in the retina and found specific
nuclear-localized MEF2C in vascular ECs and other cell
types in the retinal ganglion cell layer and inner nuclear
layer at P9 and P35 (Figure 1). MEF2C expression was
not detected in photoreceptors at this early time point,
although a recent report found MEF2C to be expressed in
interneurons in the inner nuclear layer and rod photore-
ceptors in adult retinas.39
The mouse retina has been useful as a model for
physiologic and developmental angiogenesis, in large
part because development of the retinal vasculature oc-
curs postnatally in mice.6 Although global deletion of
MEF2C results in extensive vascular malformations in the
siRNA-Treated HRECs
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AJP June 2012, Vol. 180, No. 6embryo and yolk sac,8,9 we found no effect of EC-specific
ablation of mef2c on normal retinal vascular development
(Figure 2). Because mice with global deletion of MEF2C
also exhibit severe cardiac defects,10 the vascular de-
fects observed in these mice may be secondary to the
circulatory problems resulting from the severely mal-
formed heart.
We next investigated the possible role of MEF2C in
regulating retinal ECs under pathologic circumstances
using the OIR model. We found that EC-specific ablation
of mef2c reduced retinal VO and dramatically promoted
retinal revascularization in OIR. We found a significant
decrease in retinal vessel loss in mice with EC-specific
ablation of mef2c during the hyperoxia phase at P9 (Fig-
ure 3, C–E), which is known to be the point at which peak
VO (and retinal avascularity) is reached in OIR.6 This was
associated with a significant decrease in retinal EC apop-
tosis in mutant mice.
After P9 in the OIR model, mice undergo a relatively
slow process of retinal revascularization, first during the
hyperoxia phase from P9 to P12 and subsequently during
the phase of relative hypoxia that commences when mice
are returned to a room air environment.6 In mice with
EC-specific ablation of mef2c, we found substantial en-
hancement of revascularization during the hyperoxia and
hypoxia phases (Figure 4, A and B). Consequently, the
degree of retinal avascularity was dramatically reduced
in mutant mice by P17. This was associated with a sig-
nificant reduction in pathologic retinal NV in these mice at
P17, as expected (Figure 4C), since the degree of retinal
avascularity is a major driver of pathologic NV.6 The phys-
iologic revascularization in the knockout was associated
with pericytes (Figure 4D), which are implicated in vessel
stabilization.40 In addition, the knockout mice exhibited a
significant reduction in blood-retinal barrier dysfunction
(Figure 5), supporting the conclusion that endothelial abla-
tion of MEF2C promotes physiologic revascularization and
normalization of the retinal vasculature.
We complemented the studies in mice with in vitro
studies in cultured HRECs, using an siRNA approach to
suppress MEF2C expression. We exposed HRECs to
conditions of oxidative stress since this is thought to be a
major factor in vessel loss in OIR.2 Consistent with the
findings in mouse retina during OIR, MEF2C deficiency
promoted angiogenesis in retinal ECs in vitro. Specifi-
cally, MEF2C knockdown reduced apoptosis in retinal
ECs exposed to oxidative stress (Figure 6) and enhanced
EC angiogenesis in a tube formation assay (Figure 7).
Figure 8. HO-1 mediates the inhibitory effect of MEF2C in regulating EC
tube formation under oxidative stress conditions. A: Down-regulation of
MEF2C increases HO-1 protein expression in HRECs. HO-1 protein was
detected by Western blot analysis 48 hours after HRECs were transfected with
MEF2C siRNA (siMEF2C). B: HO-1 siRNA (siHO-1) is effective in knocking
down HO-1 expression in HRECs. MEF2C and HO-1 protein were detected
by Western blot analysis 48 hours after siRNA transfection. C: Knockdown of
HO-1 significantly abrogates increased tube formation in siMEF2C-trans-
fected HRECs with or without H2O2 treatment. Representative images for
tube formation assay are shown. Scale bar 100 m. D:Quantitation of tube
formation in siRNA-transfected HRECs. Data are from the average values of
four independent experiments. Data are given as mean  SD. *P  0.01.
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; siCTL, control siRNA.
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which demonstrate a reduction in retinal EC apoptosis
and a dramatic enhancement in retinal revascularization
in mice with EC ablation of mef2c. These results confirm
an EC-autonomous role for MEF2C in regulating angio-
genesis.
To gain further insights into the antiangiogenic actions
of MEF2C in vitro, we used microarray analysis to inves-
tigate gene expression changes after siRNA-mediated
MEF2C knockdown in retinal ECs. HO-1 expression was
significantly increased and was of particular interest as a
possible mechanism for inhibition of EC apoptosis and
enhancement of angiogenesis, especially under oxida-
tive stress conditions. HO-1 is well-known to play an
important protective role for blood vessels, in large part
by mitigating the effects of oxidative stress.41–43 We,
therefore, directed additional studies toward the possible
role of HO-1 in the HREC culture system. We confirmed
that knockdown of MEF2C significantly increased HO-1
expression at the protein level in HRECs (Figure 8A). In
addition, siRNA-mediated knockdown of HO-1 sup-
pressed retinal EC tube formation in vitro under normal or
stress conditions (Figure 8, C and D). In addition, con-
comitant knockdown of HO-1 significantly abrogated the
effect of MEF2C knockdown on enhancing retinal EC
tube formation (Figure 8, C and D). This finding indicates
that the induction of HO-1 is an important mechanism of
the proangiogenic effects of knocking down MEF2C, at
least in vitro, although there are likely to be other genes
involved in this beneficial effect. Whether MEF2C has a
direct or indirect effect on HO-1 expression requires fur-
ther investigation. It will be of interest to investigate the
role of HO-1 in the regulation of retinal ECs in OIR.
Overall, these findings in vivo and in vitro indicate that
MEF2C plays an important role in retinal ECs in regulating
cellular response to stress conditions. These findings in
mice were performed using a Tie2-Cre system, which is
widely used to ablate gene expression in ECs. Of note,
this system has also been found to be active in some
hematopoietic stem cells.44 Therefore, since macro-
phages, myeloid progenitor cells, and endothelial pro-
genitor cells, which are derived from hematopoietic stem
cells, could also affect revascularization in OIR, we can-
not exclude a contribution from these other cell types to
the effects we observed.
It is becoming increasingly appreciated that reducing
retinal avascularity may be an important therapeutic strat-
egy for ischemic retinopathies, therefore making it critical
to gain a better understanding of retinal VO and revas-
cularization in OIR. Much has been discovered about the
paracrine factors in the retinal milieu that regulate the
retinal vascular response to OIR. Research into retinal
avascularity in animal models of OIR has identified mol-
ecules that can either reduce VO or enhance revascular-
ization in OIR, including insulin-like growth factor binding
protein-3,45,46 erythropoietin,47 and Norrin.48 In addition,
pathogenic molecules have been identified in OIR, in-
cluding thrombospondin-1,49 tumor necrosis factor-,50
NADPH oxidase,51–53 peroxynitrite/nitrosative stress,54,55
trans-arachidonic acids,56 and semaphorin 3A.36,57 How-
ever, less is known about the molecular determinants ofthe retinal EC response to OIR, which affects vascular
degeneration and revascularization. The present study
indicates that MEF2C is an important transcription factor
that modulates the response of retinal ECs to stress con-
ditions. Inhibiting MEF2C in retinal ECs protects the reti-
nal vasculature against degeneration and enhances nor-
mal revascularization in OIR. Modulation of MEF2C in
retinal ECs could, therefore, be a therapeutic strategy to
reduce retinal avascularity in ischemic retinopathies.
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